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Gene-expression proﬁling has had a considerable impact on our understanding of breast cancer biology.
During the last 15 years, 5 intrinsic molecular subtypes of breast cancer (Luminal A, Luminal B, HER2-
enriched, Basal-like and Claudin-low) have been identiﬁed and intensively studied. In this review, we
will focus on the current and future clinical implications of the intrinsic molecular subtypes beyond the
current pathological-based classiﬁcation endorsed by the 2013 St. Gallen Consensus Recommendations.
Within hormone receptor-positive and HER2-negative early breast cancer, the Luminal A and B subtypes
predict 10-year outcome regardless of systemic treatment administered as well as residual risk of distant
recurrence after 5 years of endocrine therapy. Within clinically HER2-positive disease, the 4 main
intrinsic subtypes can be identiﬁed and dominate the biological and clinical phenotype. From a clinical
perspective, patients with HER2þ/HER2-enriched disease seem to beneﬁt the most from neoadjuvant
trastuzumab, or dual HER2 blockade with trastuzumab/lapatinib, in combination with chemotherapy,
and patients with HER2þ/Luminal A disease seem to have a relative better outcome compared to the
other subtypes. Finally, within triple-negative breast cancer (TNBC), the Basal-like disease predominates
(70e80%) and, from a biological perspective, should be considered a cancer-type by itself. Importantly,
the distinction between Basal-like versus non-Basal-like within TNBC might predict survival following
(neo)adjvuvant multi-agent chemotherapy, bevacizumab beneﬁt in the neoadjuvant setting
(CALGB40603), and docetaxel vs. carboplatin beneﬁt in ﬁrst-line metastatic disease (TNT study). Overall,
this data suggests that intrinsic molecular proﬁling provides clinically relevant information beyond
current pathology-based classiﬁcations.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Despite that breast cancer mortality has been moderately
reduced by current treatments, more than 450,000 estimated
deaths due to breast cancer are expected annually worldwide [1].
The most plausible explanation for this scenario is that we lack a
complete picture of the biologic heterogeneity of breast cancers.
Importantly, this complexity is not fully reﬂected by the mainnd Targeted Therapeutics in
Institute (IDIBAPS), Rossello,
Ltd. This is an open access article uclinical parameters and pathological markers (oestrogen receptor
[ER], progesterone receptor [PR] and human epidermal growth
factor 2 [HER2]), all of which are routinely used in the clinic to
stratify patients for prognostic predictions, to select treatments and
to include patients in clinical trials.
Gene expression proﬁling has had a considerable impact on our
understanding of breast cancer biology. During the last 15 years, we
and others have extensively characterized 5 intrinsic molecular
subtypes of breast cancer (Luminal A, Luminal B, HER-2 enriched,
Basal-like and Claudin-low) and a normal breast-like group [2e6].
These entities have shown signiﬁcant differences in terms of their
incidence, risk factors, prognosis and treatment sensitivity.
Regarding prognosis, the Luminal A subtype has shown repeatedlynder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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datasets of patients with early breast cancer, including 6 phase III
clinical trials (TransATAC, GEICAM9906, CALGB9741, ABCSG08,
NCIC-CTG MA.5 and NCIC-CTG MA.12), where patients received
various adjuvant systemic treatments.
A particular piece of data that highlights the importance of
intrinsic subtyping in breast cancer comes from one of the most
complete molecular characterization studies that have ever been
performed in breast cancer. In this study, led by The Cancer
Genome Atlas Project (TCGA), more than 500 primary breast can-
cers were extensively proﬁled at the DNA (i.e. methylation, chro-
mosomal copy-number changes and somatic and germline
mutations), RNA (i.e. miRNA andmRNA expression) and protein (i.e.
protein and phosphor-protein expression) levels using the most
recent technologies [6]. In a particular analysis of over 300 primary
tumours (i.e. shown in Figure 2 of that publication [6]), 5 different
data-types (i.e. all except DNA mutations) were combined together
in a cluster of clusters in order to identify how many biological
homogenous groups of tumours one can identify in breast cancer.
The consensus clustering results showed the presence of 4 main
entities of breast cancer but, more importantly, these 4 entities
were found to be very well recapitulated by the 4 main intrinsic
subtypes (Luminal A, Luminal B, HER2-enriched and Basal-like) as
deﬁned bymRNA expression only [7]. Overall, these results suggest
that intrinsic subtyping captures the vast majority of the biological
diversity occurring in breast cancer.
Since 2011, the St. Gallen international expert consensus panel
adopted an intrinsic subtype-based approach for recommending
adjuvant systemic therapies (i.e. endocrine, chemotherapy and
anti-HER2 therapy) in early breast cancer [8]. Although the panel
acknowledged the superior accuracy and reproducibility of multi-
gene expression molecular assays, these assays are not readily
available for all our patients. Thus, over the years, we and others
have proposed pathology-based surrogate deﬁnitions especially for
distinguishing Luminal A from B tumours [9e11]. However, despite
important efforts to improve the various pathology-based surro-
gate deﬁnitions of the intrinsic subtypes, these continue to be
suboptimal.
Here, we review the current and the potential future clinical
implications of the intrinsic molecular subtypes of breast cancer
beyond the pathological-based surrogate classiﬁcation endorsed by
the 2013 St Gallen Consensus Recommendations [8].Intrinsic subtyping based on gene expression versus
histopathology
To date, numerous studies have evaluated and compared the
classiﬁcation of tumours based on the PAM50 gene expression
predictor with the pathology-based surrogate deﬁnitionsTable 1
Distribution of the PAM50 intrinsic subtypes within the pathology-based groups.a
IHC-based group References N PAM50
Lumina
HRþ/HER2 [10,14,16e22] 4295 60.3%
Luminal A [10,14,17,21] 637 62.2%
Luminal B [10,14,17,21] 317 34.1%
HER2þ [6,23e26] 831 17.6%
HER2þ/HRþ [25,26] 182 33.0%
HER2þ/HR [25,26] 168 19.0%
TNBC [12e15] 868 1.6%
a The data has been obtained from the different publications. Several studies have pe
based) from formalin-ﬁxed parafﬁn-embedded tumour tissues [10,14,17,19e22], wh
[6,16,18,23e26].[6,10,12e26]. To better understand the concordance between the 2
classiﬁcationmethods, we have combined the data from all of these
studies for a total of 5994 independent samples (Table 1). Of note,
the vast majority of these studies performed central determination
of pathology-based biomarkers, so this needs to be taken into ac-
count since this is not what is currently being done in the clinical
setting where each hospital determines these biomarkers. Of note,
large discrepancies (~20%) between local and central determination
of ER, PR, Ki67 and HER2 are expected [27e31].
In this combined analysis, the discordance rate between both
classiﬁcations was found to be present in almost 1 out of 3 patients
(rate ¼ 30.72% across all patients; kappa statistic ¼ 0.564, “mod-
erate agreement”; rate ¼ 44.0% within non-triple-negative disease;
kappa statistic ¼ 0.314, “fair agreement”). Across the IHC-based
subtypes, the discordance rate was 37.8%, 48.9%, 53.8%, 33.9% and
13.9% for the IHC-Luminal A, IHC-Luminal B, IHC-Luminal B/HER2þ
(to identify PAM50 Luminal B), HR/HER2þ (to identify PAM50
HER2-enriched) and triple-negative (to identify PAM50 Basal-like)
subtypes, respectively. These results clearly suggest that the 2
methods to identify intrinsic biology should not be considered the
same. The most likely explanation is that 3 or 4 biomarkers do not
fully recapitulate the intrinsic subtypes of breast cancer. For
example, we compared the prognostic and predictive ability of a 3-
gene subtype classiﬁer based on ESR1, ERBB2 and AURKA compared
with the 50-gene PAM50 intrinsic classiﬁer, and the 50-gene assay
was signiﬁcantly better [4]. In fact, during the development of the
clinically applicable PAM50 intrinsic subtype predictor, 50 genes
was found to be the minim number of genes needed to robustly
identify the 4 main intrinsic subtypes without compromising its
accuracy [4].Main molecular features of the intrinsic subtypes
Four main intrinsic molecular subtypes of breast cancer
(Luminal A, Luminal B, HER2-enriched and Basal-like) have been
characterized over the last 15 years. At the RNA and protein level,
Luminal A and B subtypes are largely distinguished by the
expression of two main biological processes: proliferation/cell
cycle-related and luminal/hormone-regulated pathways (Fig. 1).
Compared to Luminal A tumours, Luminal B tumours have higher
expression of proliferation/cell cycle-related genes or proteins (e.g.
MKI67 and AURKA) and lower expression of several luminal-
related genes or proteins such as the progesterone receptor (PR)
[32] and FOXA1, but not the oestrogen receptor [10], which is found
similarly expressed between the two luminal subtypes and can
only help distinguish luminal from non-luminal disease. At the
DNA level, Luminal A tumours show a lower number of mutations
across the genome, lower number of chromosomal copy-number
changes (e.g. lower rates of CCND1 ampliﬁcation), less TP53intrinsic subtype distribution








rformed a standardized version of the PAM50 assay (RT-qPCR-based or nCounter-
ile others have performed the microarray-based version of the PAM50 assay
Fig. 1. Intrinsic subtype identiﬁcation using the PAM50 subtype predictor. (A) PAM50 unsupervised gene expression heatmap of 1,834 breast cancer samples proﬁled at the
Translational Genomics Group at VHIO. The subtype calls of each sample are shown below the array tree. Each square represents the relative transcript abundance. (B) Principal
component 1 and 2 loading plots of the same dataset shown in (A) using the PAM50 genes-only.
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more PIK3CA (45% vs. 29%) and MAP3K1 mutations (13% versus 5%)
compared to Luminal B tumours [6]. Interestingly, a subgroup of
Luminal B tumours is found hypermethylated, and a subgroup of
Luminal A (6.3e7.8%) and Luminal B (16.4e20.8%) tumours show
HER2-ampliﬁcation/overexpression (see below).
The HER2-enriched subtype is characterized at the RNA and
protein level by the high expression of HER2-related and
proliferation-related genes and proteins (e.g. ERBB2/HER2 and
GRB7), intermediate expression of luminal-related genes and pro-
teins (e.g. ESR1 and PGR) and low expression of basal-related genes
and proteins (e.g. keratin 5 and FOXC1). At the DNA level, these
tumours show the highest number of mutations across the genome,
and 72% and 39% of HER2-enriched tumours are TP53 and PIK3CA
mutated, respectively. Although the majority (68%) of HER2-
enriched tumours have ERBB2/HER2 overexpression/ampliﬁca-
tion, we should expect to identify the HER2-enriched subtype
within HER2-negative disease (see below). Interestingly, the HER2-
enriched subtype has been found uniquely enriched for tumours
with high frequency of APOBEC3B-associated mutations [33].
APOBEC3B is subclass of APOBEC cytidine deaminases, which
convert cytosine to uracil and has been implicated as a source of
mutations in many cancer types [34].
The Basal-like subtype is characterized at the RNA and protein
level by the high expression of proliferation-related genes (e.g.
MKI67) and keratins typically expressed by the basal layer of the
skin (e.g. keratins 5, 14 and 17), intermediate expression of HER2-
related genes, and very low expression of luminal-related genes.
At the DNA level, these tumours show the second highest number
of mutations across the genome, mostly are hypomethylated, and
80% and 9% of Basal-like tumours are TP53 and PIK3CA mutated,
respectively. BRCA1-mutated breast cancer is associated with
Basal-like disease [35,36]. Finally, ERBB2/HER2 overexpression/
ampliﬁcation is found in 2.1e17.4% of tumours with a Basal-like
proﬁle.Basal-like versus not classiﬁcation: biological and
epidemiological implications
The TCGA comprehensive molecular characterization of breast
cancer conﬁrmed that among all the intrinsic subtypes, the Basal-
like is the most distinct [6]. This observation ﬁts with previous
molecular studies and with clinical data that shows that triple-
negative breast cancer tends to affect young women, is associated
with BRCA1 mutations and is a highly aggressive disease [37].
However, how different is Basal-like disease from the rest of breast
cancer subtypes?
Two recent studies have addressed this question from a biolog-
ical perspective [38,39]. In the ﬁrst one, we evaluated global
microarray-based gene expression proﬁles of a combined dataset
composed of 6 different cancer-types obtained from the TCGA
project and that included 542 primary breast cancers [38]. The un-
supervised results revealed that a subgroup of breast cancers,
virtually all Basal-like by PAM50, should be considered a molecular
entity by itself just like ovarian or colorectal cancer, and that>70%of
Basal-like breast cancers were more similar to squamous cell lung
cancer than to Luminal A or B disease [38]. In the second study, the
panCancer TCGA study group combined all the available molecular
data (except mutations) across 12 cancer types, including 845 pri-
mary breast cancers [39]. Unsupervised classiﬁcation using all data-
types revealed a similar ﬁnding as the previous study, namely that
Basal-like breast cancer is a unique entity and much different from
the rest of breast tumours. Interestingly, the other cancer-type that
showed such a large biological heterogeneity was bladder cancer
which could be re-classiﬁed into 3 distinct molecular entities, one
being similar to the Basal-like breast cancer subtype [39].
Despite in vivo preclinical data suggesting that breast cancer
disease arises from the transformation of a common luminal pro-
genitor [40e42], this biological result with human tumours
strongly suggest that 2 very different cell-types of origin exist in the
mammary gland; one whose transformation gives rise to Basal-like
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Basal-like disease. This hypothesis is further supported by epide-
miological data [43]. For example, a bimodal age distribution at
diagnosis with peak frequencies near ages 50 and 70 years is a
known fundamental characteristic of breast cancer [43]. The
bimodal peak frequencies at diagnosis suggest that a “mixture” of
twomain populations exist in breast cancer. Not surprisingly, when
intrinsic subtyping was evaluated, the two main populations were
largely explained by the Basal-like versus not nature of the tumour
[43], with Basal-like tumours explaining the early-onset age peak.
Another example is work by Millikan and colleagues [44] look-
ing at risk factors of breast cancer in a population-based, case-
econtrol study of African-American and white women. The results
revealed that Luminal A disease exhibits risk factors typically re-
ported as protective for the development of breast cancer, including
increased parity and younger age at ﬁrst full-term pregnancy; on
the other hand, Basal-like cases exhibits several associations that
were opposite to those observed for Luminal A, including increased
risk for parity and younger age at ﬁrst term full-term pregnancy
[44]. Moreover, longer duration breastfeeding, increasing number
of children breastfeed, and increasing number of months breast-
feeding per child were each associated with reduced risk of Basal-
like breast cancer, but not luminal A [44]. Overall, this data suggests
that we should clearly separate these two entities when we talk
about breast cancer.
Clinical implications within HRþ/HER2-negative disease
Prognostic implications
Within HRþ/HER2-negative breast cancer, 90e95% of tumours
fall into the LuminalAandBsubtypes. In earlybreast cancer, Luminal
B disease has worse baseline distant recurrence-free survival at 5-
and 10-yrs regardless of adjuvant systemic therapy compared to
Luminal A disease. This has now been observed in multiple retro-
spective datasets, including 6 phase III clinical trials (i.e. CALGB9741
[45], GEICAM9906 [46], TransATAC [19], ABCSG-08 [20], MA.5 [47]
and MA.12 [17] trials) coming from different countries and pop-
ulations and with different adjuvant systemic therapies (i.e.
endocrine-only, chemotherapy-only and both). In the vast majority
of studies, the three main variables that predict outcome in early
breast cancer are nodal status, tumour size and intrinsic subtyping.
Of note, the vast majority of these studies with long-term
follow-up show that the survival curves of Luminal B tumours
cross the survival curves of Basal-like disease at around ~10-years
of follow-up. Thus, although at 5-years of follow-up, Basal-like
disease has a worse outcome than Luminal B tumours, this is not
the case at 10 years. This result suggest that if we are to make an
impact in decreasing themortality of early breast cancer, we should
focus on ﬁnding additional therapies for Luminal B disease since
this tumour subtype is very frequent (i.e. represent ~30e40% of all
breast cancer diagnoses) and chemotherapy and endocrine thera-
pies are not enough for the majority of these patients.
A part from predicting baseline prognosis, the Luminal A vs B
classiﬁcation, together with tumour size and nodal status, predicts
the residual risk of recurring at a distant site within the 5e10-years
of follow-up (the so called late recurrence). In a retrospective
analysis of the ABCSG-08 study, late distant relapse-free survival
was found signiﬁcantly different between Luminal A and B subtypes
in all patients and in the node-negative subgroup [48]. Similar re-
sults have been observed in the TransATAC study and in a pooled
analysis of both studies looking at the PAM50 Risk of Recurrence
(ROR) score [49,50]. These results suggest that intrinsic subtype has
the ability to inform decisions concerning the length of endocrine
therapy (i.e. 5 vs 10 years), being the low-risk Luminal A tumourswith low tumour burden (e.g. tumour size 1 cm and node-negative)
the group were 5 years of endocrine therapy might be sufﬁcient.
Cytotoxic therapy beneﬁt
Most of the direct evidence of general chemo-sensitivity of the
Luminal A and B subtypes comes from the neoadjuvant setting. For
example, in a cohort of 208 patients with luminal disease treated
with anthracycline/taxane-based chemotherapy and with patho-
logic complete response (pCR) data, the pCR rates in patients with
the Luminal A and B subtypes were 3% and 16% (odds ratio ¼ 6.01,
p-value ¼ 0.003), respectively [4,51]. Similar results have been
obtained with the pathology-based surrogate deﬁnitions of both
luminal subtypes [52e54]. Overall, this data suggest that among
the 2 luminal subtypes, the Luminal A tumours are less chemo-
sensitive than Luminal B tumours. This hypothesis is further sus-
tained by the fact that pCR is not predictive of survival outcome in
IHC-Luminal A tumours [53] and in patients with HRþ/HER2/low-
grade [55], but it is predictive of outcome in IHC-Luminal B/HER2-
negative [53] and in HRþ/HER2/high-grade [55]. Furthermore,
indirect evidence comes from the retrospective results of the
OncotypeDX Recurrence Score, a prognostic gene expression-based
test, where low-risk patients, which are basically a subset of
Luminal A tumours, did not show a survival beneﬁt from multi-
agent adjuvant chemotherapy in the NSABP-B20 (CMF or CF regi-
mens) [56] and SWOG8814 (FAC regimen) [57].
Even if one assumes that all patients beneﬁt to the same extend
from multi-agent chemotherapy [58], intrinsic subtyping together
with prognostic factors such as tumour size and nodal status can be
used to help decide when adjuvant chemotherapy should not be
administered because the risk of relapsingwithout it is very low. For
example, if the risk of relapsing at distant sites of a patient is esti-
mated to be10% without chemotherapy, the absolute beneﬁt from
chemotherapywouldbe3% (assuminga30% reductionof the riskof
10-year overall mortality for all patients as suggested by the Oxford
overview [58]). This absolute beneﬁt barely exceeds the approxi-
mately 1% life-threatening toxicities of chemotherapy [59,60].
Although Luminal A tumours seem to beneﬁt less from multi-
agent chemotherapy than Luminal B tumours, this does not pre-
clude that this group of tumours cannot beneﬁt from particular
cytotoxic agents or regimens. For example, a retrospective analyses
of the GEICAM9906 study (FECx6 vs. FECx4 and weekly paclitaxel)
and CALGB9342/9840 (3-weekly paclitaxel vs. weekly paclitaxel)
showed that low-proliferative tumours, mostly a subset of Luminal
As, beneﬁt substantially from the weekly paclitaxel regimen
whereas high proliferative tumours did not [46]. Although this was
a hypothesis-generating result, one should wonder if lower-dose
but more continuously administered chemotherapy might be
more beneﬁcial in these low-proliferative Luminal A tumours
instead of 3-weekly and high-dose regimens. In fact, in a retro-
spective analysis of a 10-year follow-up of the phase 3 randomized
BCIRG-001 trial (FAC vs. TAC), the only subtype that did not beneﬁt
from 3-weekly docetaxel instead of 3-weekly 5-FU in terms of
disease-free survival was the IHC-Luminal A (IHC-Luminal A vs.
IHC-nonLuminal A interaction p-value ¼ 0.031) [62]. Further
studies are needed to determine if Luminal A tumours beneﬁt from
chemotherapy or speciﬁc chemotherapeutic agents/regimens or
even CDK4/6 inhibitors. This answer would be especially relevant
in the clinic for those patients with Luminal A tumours with high
tumour burden (intermediate or high-risk).
Endocrine therapy beneﬁt
Regarding the beneﬁt from endocrine therapy, both tumour
subtypes have shown to derive a similar relative beneﬁt by looking
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treatment with an aromatase inhibitor in the neoadjuvant setting
[16]. However, since Luminal A tumours have a lower baseline
proliferation status than Luminal B tumours, a larger proportion
can achieve low post-treatment values. In fact, in a retrospective
analysis of the ACOSOG Z1031 phase II trial, where patients with
stage 2 or 3 ER-high/HER2-negative disease were treated for 4e4.5
months with a neoadjuvant aromatase inhibitor [18], a larger
proportion of Luminal A tumours achieve a pre-operative prog-
nostic index (PEPI) score of 0 (i.e. good outcome without chemo-
therapy) compared to Luminal B tumours (27.1 vs. 10.7%, P-
value ¼ 0.004). PEPI compares 4 clinical-pathological variables
before and after treatment (i.e. tumour size, nodal status, Ki67 and
Allred ER score) and has been prognostically validated in an inde-
pendent study of 203 postmenopausal women of the IMPACT trial
[63].
At the adjuvant setting, the only data that we are aware of is the
result coming from the BCIRG-001 phase III adjuvant clinical trial
(TAC vs FAC), where IHC-Luminal A tumours showed a higher
beneﬁt from adjuvant tamoxifen than IHC-Luminal B tumours
(tamoxifen vs. no tamoxifen hazard ratio ¼ 0.15 vs. 0.44) [64].
However, allocation to tamoxifen therapy was not based on
randomization and thus this result should be interpreted with
caution.
Implications of the nonluminal subtypes
Within HRþ/HER2-negative early disease, it is expected to
identify a subpopulation of non-luminal subtypes (i.e. HER2-
enriched and Basal-like) by gene expression (Table 1). HER2-
enriched tumours seem to represent 5.5e11.0% of all HRþ/HER2-
negative cases depending on the dataset evaluated, whereas
Basal-like tumours represent around ~1e5%. Based on the molec-
ular features of these two non-luminal subtypes, one would expect
to identify these tumours in patients with tumours that express
low-ER. In fact, a study performed intrinsic subtyping in 25 tumour
samples with 1e9% ER-positive tumour cells, and found that 80%
were nonluminal (48% Basal-like and 32% HER2-enriched) [65]. On
the other hand, a combined analysis of 48 borderline cases (1e10%
ERþ tumour cells) from the MA.5, MA.12 and GEICAM9906
revealed that 46.0% were nonluminal (29% HER2-enriched and 17%
Basal-like) [66]. Moreover, HER2-enriched and Basal-like tumours
can still be identiﬁed in tumours that have very high expression of
ER as exempliﬁed by the 6 non-luminal tumours (representing 2.9%
of the entire cohort) identiﬁed in the Z1031 trial where patients'
tumours were all Allred ER score of 6e8.
In terms of survival outcome, we evaluated the prognostic value
of the intrinsic subtypes in a cohort of 1380 patients with ERþ/
HER2-unknown early breast cancer treatedwith 5 years of adjuvant
tamoxifen-only across several retrospective studies [67]. Non-
luminal subtypes represented 9% (7% HER2-enriched and 2% Basal-
like) of the samples, and each nonluminal subtype showed a sig-
niﬁcant worse outcome compared to Luminal A subtype in both
node-negative and node-positive disease. This data suggest that
HER2-enriched and Basal-like diseases might not beneﬁt much
from endocrine therapy despite being ERþ. In fact, in the Z1031 trial
[18], the single Basal-like patient demonstrated high pre- and post-
treatment Ki67 values consistent with endocrine therapy resistance
(38% and 26.8%, respectively). All ﬁve HER2-enriched patients had
persistently high surgical Ki67 levels (20%), consistent with high-
level oestrogen-independent growth.
In another retrospective study [16] of 112 postmenopausal
women with stages IeIIIB ERþ early breast cancer before and after
2-weeks’ anastrozole treatment in a neoadjuvant trial, Basal-like
(n ¼ 3 [2.7%]; mean Ki-67 change of þ15.3%) and HER2-enriched(n ¼ 9 [8.0%]; mean Ki-67 change of 50.7%) subtypes generally
showed poorer response compared to Luminal A or B subtypes
(mean Ki-67 change of 75%) [16]. Interestingly, this study proﬁled
post-treatment samples. As expected, the vast majority of Luminal
A samples (31/32, 97%) continued being Luminal A or became
normal breast-like (likely suggesting tumour response and
contamination by normal tissue) [16]. On the other hand, although
the majority of Luminal B tumours became Luminal A (9/17, 53%) or
normal breast-like (3/17,18%), a substantial proportion of Luminal B
tumours (5/17, 30%) remained Luminal B or became HER2-enriched
[16]. Although encouraging, further data is needed in order to use
intrinsic subtyping during treatment as a biomarker of treatment
sensitivity.
Clinical implications within HER2-positive disease
Distribution and biology of the intrinsic subtypes
Similarly as the other pathology-based groups, all the intrinsic
molecular subtypes can be identiﬁed within clinically HER2-
positive disease albeit with different proportions. In our com-
bined analysis of 831 HER2þ tumours (Table 1), 44.6%, 26.8%, 17.6%
and 11.0% were identiﬁed as HER2-enriched, Luminal B, Luminal A
and Basal-like. Interestingly, HR-status by IHC does not fully reca-
pitulate the intrinsic subtypes since 20.9% (1 out of 5 patients) of
HER2þ/HRþ tumours will be identiﬁed as non-luminal (18.7%
HER2-enriched and 2.2% Basal-like), and 23.2% of HER2þ/HR tu-
mours will be identiﬁed as luminal (19.0% Luminal A and 4.2%
Luminal B) and 10.7% as Basal-like.
From a biological perspective, a particular unanswered question
was how different is an intrinsic subtype based on HER2 status. For
example, how different is HER2þ/Luminal A disease from a classical
HER2-negative/Luminal A disease? We recently approached this
question by interrogating The Cancer Genome Atlas (n ¼ 495) and
Molecular Taxonomy of Breast Cancer International Consortium
(METABRIC) datasets (n ¼ 1730) of primary breast cancers for
molecular data derived from DNA, RNA and protein, and deter-
mined intrinsic subtype. Within each subtype, only 0.3%e3.9% of
genes were found differentially expressed between HER2þ and
HER2-negative tumours. As expected, the vast majority of differ-
entially expressed genes originated in the 17q12 DNA amplicon
where the ERBB2 gene is located. Within HER2þ tumours, HER2
gene and protein expressionwas statistically signiﬁcantly higher in
the HER2-enriched subtype than either luminal subtype. Thus, this
result suggests that intrinsic subtype dominates the biological
phenotype within HER2þ and HER2-negative disease.
Prognostic implications
Two large studies have evaluated the prognostic value of HR
status (i.e. a surrogate manner of looking at luminal vs non-luminal
disease) within HER2þ breast cancer [68,69]. In the 4-year follow-
up of the N9831 and National Surgical Adjuvant Breast and Bowel
Project B-31 adjuvant trials of trastuzumab in HER2þ disease
(n ¼ 4045), HR-positive disease was found statistically signiﬁcantly
associated with approximately 40% increased disease-free survival
and overall survival, compared to hormone receptor-negative dis-
ease [68]. This association of hormone receptor status with survival
was found to be independent of the main clinical-pathological
variables, including trastuzumab administration. Similar results
were observed in a prospective cohort study of 3394 patients with
stage I to III HER2þ breast cancer from National Comprehensive
Cancer Network centres [69]. In both studies, HR-negative disease
experienced more cancer relapse in the ﬁrst 5 years than HR-
positive [69]. Interestingly, patients with HR-negative tumours
A. Prat et al. / The Breast 24 (2015) S26eS35 S31were less likely to experience ﬁrst recurrence in bone and more
likely to recur in brain, compared to patients with hormone
receptor-positive tumours [69]. Better outcomes independently of
treatment in the HR-positive group compared to the HR-negative
have also been observed in the NeoALTTO [70] and ALTTO [71]
clinical trials.
Regarding intrinsic subtyping, we have recently evaluated the
prognostic value of these entities in a large retrospective cohort of
1730 patients from the UK and Canada with and without HER2þ
disease treated in the adjuvant setting with different treatments
except trastuzumab [24]. The results revealed that intrinsic sub-
types are an independent prognostic variable beyond tumour size
and nodal status, and HER2þ/Luminal A tumours showed a similar
outcome compared to HER2-negative/Luminal A tumours [23].
Overall, this data suggests that Luminal A disease could be used, in
the future, together with tumour size and nodal status, to help
better identify those patients with a low risk of relapsing and thus
safely treated with less intense chemotherapy such as the adjuvant
regimen paclitaxel and trastuzumab recently proposed for “small”
(i.e. <3.0 cm) and node-negative HER2þ breast cancer [72].
Anti-HER2 treatment beneﬁt
In early breast cancer, two randomised neoadjuvant clinical
trials tested trastuzumab versus not in combination with chemo-
therapy in HER2þ breast cancer [73,74]. In the NOAH study, HR
status was found predictive of pathological complete response (48%
for HR-negative vs. 18% for HRþ; p ¼ 0.002) [75]. Overall, pCR was
found predictive of event-free survival (EFS) and overall survival;
concordant with this, patients with HR-negative tumours beneﬁted
more from trastuzumab than HRþ patients (hazard ratio for
EFS ¼ 0.58 in HR-negative vs. ¼ 0.74 in HRþ disease) [76]. When
intrinsic subtyping was evaluated in a subset of patients (46.7%) of
the NOAH study, patients with HER2-enriched disease showed a
higher beneﬁt of adding trastuzumab in terms of pCR and EFS
compared to non-HER2-enriched disease [25].
Although the NOAH results make a lot of sense from a biological
perspective, the larger beneﬁt from trastuzumab in HR-negative
disease compared to HR-positive disease has not been observed
in the 3 large adjuvant clinical trials evaluating 1-year of trastu-
zumab vs. placebo and both HR groups seem to beneﬁt similarly
[77,78]. Concordant with this, in one of these studies, the NSABP-
B31 trial, all the intrinsic subtypes beneﬁt similarly from trastu-
zumab [79]. Somewhat surprising, intrinsic subtyping in this study
was not found to be prognostic. One main difference between the
NOAH and the adjuvant trials is that the former was a poorer
outcome population (e.g. overall survival at 5 years with trastu-
zumab: ~75% in the NOAH trial vs. ~90% in the combined N9831 and
NSABP-B31 dataset). Although risk by itself should not be a pre-
dictor of therapeutic beneﬁt, it might reﬂect differences in under-
lying biology which should be the ultimate responsible for the
differentially response.
Indirect data from the neoadjuvant setting suggests that even
patients with Luminal A/HER2þ or B/HER2þ tumours beneﬁt from
trastuzumab. In the CALGB40601 trial, where patients with HER2þ
disease were randomized to neoadjuvant paclitaxel with anti-HER2
therapy (i.e. lapatinib, trastuzumab or the combination), the pCR
rates of Luminal A/HER2þ tumours or Luminal B/HER2þ tumours
were 30e40% [26]. These pCR rates are clearly higher than the ones
expected with a single taxane without trastuzumab. For example,
in the same study, the pCR rates in Luminal A/HER2þ and Luminal
B/HER2þ tumours treated with paclitaxel and lapatinib were 9%
and 22%, respectively.
Another important clinical question is which patients with
HER2þ disease beneﬁt the most from adding a second anti-HER2agent to trastuzumab and chemotherapy. In a retrospective anal-
ysis of the CALGB40601 neoadjuvant trial, the HER2-enriched
subtypes seemed to be the only intrinsic subtype to increase pCR
rates (although not statistically signiﬁcantly) with dual HER2
blockade versus trastuzumab-only (80% vs. 71%) [26]. This ﬁts with
recent survival data from the NeoALTTO and ALTTO trial in HER2þ
early breast cancer showing that HR-negative tumours obtain a
larger beneﬁt (although not statistically signiﬁcant) than HRþ tu-
mours following (neo)adjuvant chemotherapy and dual HER2
blockade (i.e. trastuzumab and lapatinib) compared with chemo-
therapy and trastuzumab-only [70,71]. Overall, the evidence so far
suggests that all the intrinsic subtypes beneﬁt from trastuzumab
(although HER2-enriched might beneﬁt the most), and the beneﬁt
of adding a second anti-HER2, especially in the context of chemo-
therapy, might reside in the HER2-enriched subtype. Further
studies are needed to shed light on the prognostic value and anti-
HER2-sensitivity of the intrinsic subtypes within HER2þ breast
cancer.
Finally, the intrinsic subtypes might be to help identify those
patients with HER2þ early breast cancer that might be successfully
treated with dual HER2 blockade (þ/ endocrine therapy) but
without chemotherapy since theirs tumours are exquisitely sensi-
tive to anti-HER2 therapy. Indeed, there is clinical evidence sug-
gesting that these patients exist. For example, the pCR rates in the
chemotherapy-free arm of the NeoSphere (n ¼ 107; 4 cycles of
pertuzumab þ trastuzumab) and TBCRC006 (n ¼ 64; 12 weeks of
lapatinib þ trastuzumab and endocrine therapy if HRþ) neo-
adjuvant studies were 16.8% and 27.0%, respectively [80e82]. In
both studies, HR-negative tumours achieved higher pCR rates than
HRþ tumours. Interestingly, in a recently reported neoadjuvant
study, the TBCRC023, comparing 12-week versus 24-week of
lapatinibþ trastuzumab treatment (and endocrine therapy if HRþ),
the pCR rate in the HRþ tumours was 33.2%, suggesting that longer
treatment in HRþ tumours might reach similar pCR rates as
chemotherapy plus two anti-HER2 agents [83]. However, no data
on intrinsic subtype is available to date from these studies. Based on
the prior knowledge, one can speculate that, regardless of HR sta-
tus, the HER2-enriched subtype enriches for the identiﬁcation of
patients that are more likely to achieve a pCR with dual HER2
blockade without chemotherapy. We are currently testing this hy-
pothesis in a prospective neoadjuvant clinical trial called PAMELA
(NCT01973660), which is similar to TBCRC006 and TBCRC023 trials,
but treatment lasts for 18-weeks.
Clinical implications within triple-negative (TN) disease
Distribution and biology of the intrinsic subtypes
In the past, we have used the word TN and Basal-like inter-
changeably. However, within TN disease, all the intrinsic molecular
subtypes can be identiﬁed, although the vast majority fall into the
Basal-like subtype (86%; range 56%e95%, depending from the
study). In our combined analysis of 868 TN tumours (Table 1),
86.1%, 9.1%, 3.2% and 1.6% were identiﬁed as Basal-like, HER2-
enriched, Luminal B and Luminal A, respectively. Although the
correlation between pathological and gene expression proﬁling is
moderate, this pathology-based subset is the one with the greatest
consistency between both classiﬁcations. Of note, we did not
evaluate the presence of the Claudin-low subtype [5].
At the same time, other gene expression-based classiﬁcations of
TN disease have emerged over the years. For example, Lehmann
and colleagues described 6 molecular subtypes of TN breast cancer:
two Basal-like (BL1 and BL2), an immunomodulatory (IM), a
mesenchymal (M), a mesenchymal stem-like (MSL) and a luminal
androgen receptor subtype (LAR) [84,85]. As expected, Lehmann's
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and, with the exception of LAR group, all other subtypes were
mostly identiﬁed as Basal-like by PAM50 (BL199%, BL2 95%, IM 84%,
M 97%, MSL 50%). Interestingly, the LAR subtype was predomi-
nantly identiﬁed as either HER2-enriched (74%) or Luminal B (14%).
In another recent study, Burstein and colleagues [86] classiﬁed TN
disease into 4 main groups: LAR, mesenchymal (MES), Basal-like
immune-suppressed (BLIS) and Basal-like immune-activated
(BLIA). Again, most PAM50 non-Basal-like tumours were identiﬁed
as LAR by this classiﬁcation, and most PAM50 Basal-like were BLIS
and BLIA. Thus, we can conclude that TN disease is biologically
heterogeneous and that although Basal-like disease predominates
(þ/ immune activation and/or inﬁltration), there is a small group
of non-Basal-like tumours (mostly LARs, or HER2-enriched) [15,87].
Prognostic implications
No data is available regarding the prognostic impact of the
intrinsic molecular subtypes deﬁned by PAM50 within TN disease.
Regarding the Lehmann's classiﬁcation, the 7 subtypes have been
evaluated retrospectively in several publicly available cohorts of TN
disease treated with different adjuvant therapies [84,85,87].
Although no clear results were obtained, several tendencies were
observed in both studies. For example, the M group showed the
worse outcome and the IM group showed a relatively better
outcome. Regarding the LAR group, one study showed a worse
outcome and another one a tendency for the best outcome. In
Burstein and colleagues [86], the only group that showed a different
outcome from the rest was the BLIA, which is consistent with the
known prognostic impact of immune inﬁltration in TN disease
[88,89]. However, the BLIA group, or the Basal-like with immune
inﬁltration, has a high risk of relapsing (~20%). Thus, this data
suggests that subtyping within TN will not have a clinical impact
based on prognosis-only since no group has such an outstanding
outcome that would allow avoiding chemotherapy.
Polychemotherapy beneﬁt
Polychemotherapy is highly effective in high proportion of pa-
tients with TN early breast cancer [55,90,91]. In the neoadjuvant
setting, pCR rates following anthracycle/taxane-based chemo-
therapy is 25e35% and patients that achieve a pCR have a better
outcome than those that do not (hazard ratio for EFS ¼ 0.24,
0.09e0.27) [55,90]. Thus, two relevant clinical questions are the
following: 1) can we identify at diagnosis or after primary surgery
those patients that are likely to be cured with local therapy and
polychemotherapy and 2) canwe identify biological processes and/
or targets associated with chemotherapy sensitivity or resistance?
To try to address the ﬁrst question, we analysed intrinsic sub-
types and various gene expression-based signatures in 5 indepen-
dent cohorts (2 neoadjuvant and 3 adjuvant), including 1 phase II
and 2 phase III clinical trials (GEICAM2006/03, GEICAM9906 and
CALGB9741), of patients with TN disease and/or Basal-like disease
treated with polychemotherapy [12]. In this study, we identiﬁed
signiﬁcant associations between genomic signatures and response
and survival after polychemotherapy within Basal-like disease-only
and not within TN disease as a whole. In other words, non-Basal-
like tumours within TN disease were contaminating the popula-
tion and adding noise to the association being evaluated. This
observation makes sense based on the huge biological and epide-
miological differences among the two groups (see above). Overall,
this result argues that clinical trials evaluating TN disease should
consider using gene expression data to stratify patients by the
Basal-like versus not classiﬁcation given the impact that this het-
erogeneity might have on the primary end points of these trials.To try to address the second question, we observed that, within
TN disease falling into the Basal-like subtype, high expression of a
previously identiﬁed proliferation signature, or low expression of a
luminal signature, was independently associated with pCR and
improved survival following polychemotherapy across different
cohorts [12]. Thus, gene expression-based signatures within an
already deﬁned homogenous group of tumours (TN and Basal-like)
can further stratify patients and provide clinically relevant infor-
mation. For example, high-risk tumours of the Basal-like subtype
with high proliferation scores are very sensitive to chemotherapy
and it may be possible that the typical standard of care treatment
for this group (i.e. anthracycline/taxane neo/adjuvant regimens) is
effective and sufﬁcient. Conversely, those Basal-like tumours pre-
dicted to be less responsive, or to have a worse prognosis despite
the standard polychemotherapy, may be appropriate for studies of
novel agents or approaches. Some patients might be particularly
sensitive to speciﬁc additional drugs like platinum agents, which
increase pCR rates in TN disease [91,92], or other cytotoxics, as will
be tested in the upcoming CIBOMA/2004-01/GEICAM/2003-11
phase III clinical trial that focuses on adjuvant capecitabine main-
tenance therapy after conventional induction chemotherapy in 876
patients with TN disease. Novel therapies that target lower-
proliferating cells (i.e. mesenchymal/claudin-low-like and/or
luminal-like cells) might be warranted in patients with TN tumours
of the Basal-like subtype that show low expression of proliferation
features.Carboplatin treatment beneﬁt
The standard polychemotherapy regimen in early breast cancer
is based on anthracycline/taxane-based combinations. However,
preclinical data suggest that Basal-like breast cancers are more
sensitive to interstrand crosslinking agents that damage the DNA
such as platinum, because of deﬁciencies in the BRCA-associated
DNA repair mechanism. To date, two clinical trials (i.e.
CALGB40603 and GeparSixto) have tested the impact of adding
carboplatin to an anthracycline/taxane-based regimen in TN early
breast cancer in the neoadjuvant setting [91,92]. The two studies
showed that carboplatin increases the pCR rate by an absolute 15%
in the entire population. In the CALGB40603 trial, a retrospective
gene expression-based analysis identiﬁed a 13.0% of nonBasal-like
disease at baseline. In patients with Basal-like tumours (83.0%),
pCRs rose from 47% to 61% with the addition of carboplatin
(p¼ 0.014), an increment which did not differ signiﬁcantly from the
overall study population (interaction p ¼ 0.93). Thus, further
studies (e.g. GeparSixto) are needed to evaluate if the Basal-like vs.
not classiﬁcation is useful for identifying those patients that might
beneﬁt or not from adding carboplatin to standard poly-
chemotherapy in early TN breast cancer.
In the ﬁrst-line metastatic setting, the TNT phase III trial ran-
domized 376 patients with TN or BRCA1/2 breast cancer disease to
carboplatin versus docetaxel [93]. Overall response rate and me-
dian progression-free survival did not differ between the two arms
[93]. However, intrinsic subtyping in 210 patients with TN disease
identiﬁed 17.1% tumours as nonBasal-like. More importantly, the
Basal-like vs. not classiﬁcation predicted ORR to carboplatin vs.
docetaxel (interaction p ¼ 0.01). Patients with nonBasal-like dis-
ease were more sensitive to docetaxel than carboplatin (73% vs.
16%), whereas patients with Basal-like disease showed similar
sensitivity (32.6% vs. 35.2%). Of note, in this study, BRCA1/2
mutated tumours (n ¼ 43) beneﬁted more from carboplatin than
docetaxel compared to nonBRCA1/2 mutated tumours (ORR 68% vs.
33%; interaction p ¼ 0.01), thus this is likely another biomarker of
platinum sensitivity, most likely within Basal-like disease.
A. Prat et al. / The Breast 24 (2015) S26eS35 S33Anti-VEGF therapy beneﬁt
Bevacizumab, an anti-VEGFmonoclonal antibody, is approved in
Europe for HER2-negative metastatic breast cancer in combination
with paclitaxel or capecitabine. However, in the USA, safety and
toxicity risks do not seem to outweigh the ability of bevacizumab to
signiﬁcantly prolong progression-free survival. Thus, ﬁnding bio-
markers that can help us identify which patients beneﬁt the most
from this treatment strategy seems logical. In this regard, the
CALGB40603 trial recently tested the impact of adding bev-
acizumab to standard neoadjuvant anthracycline/taxane-based
chemotherapy in TN early breast cancer. The results showed that
in the general TN population (n ¼ 443), bevacizumab increased the
pCR rates in the breast (59% vs. 48%; p ¼ 0.0089). In a subsequent
retrospective analysis of 367 samples, a greater beneﬁt from bev-
acizumabwas observed in Basal-like disease (i.e. pCR rose from 45%
to 64%, p ¼ 0.0009), but not in non-basal-like disease (i.e. pCR
decreased from 60% to 43%; interaction p ¼ 0.024). Thus, this is
another example of how the Basal-like versus not classiﬁcation can
predict sensitivity to a particular treatment strategy. Further
studies are needed to determine if Basal-like disease is a biomarker
of response or beneﬁt from bevacizumab, especially in the meta-
static setting where it is still approved in some countries.
Antiandrogen therapy beneﬁt
Based on the biology of the different intrinsic subtypes within
TN disease, one can speculate that the non-Basal-like (i.e. Luminal
A, Luminal B and HER2-enriched) or LAR group might beneﬁt from
antiandrogens. In fact, a preclinical study revealed that TN cell lines
that overexpress the androgen receptor, and which fall into the LAR
or Luminal B subtypes (i.e. MDA-MB453 and SUM185PE), are highly
sensitive to bicalutamide [84,85]. In the clinical setting, we have
indirect evidence suggesting that patients with TN disease that fall
into these subtypes beneﬁt from anti-androgens. Gucalp and col-
leagues [94] completed a phase II trial of bicalutamide 150 mg daily
in patients with metastatic ER-/PR-negative but AR-positive by IHC.
Among 424 ER-/PR-negative patients, 12% tested ARþ. The clinical
beneﬁt rate was 19% (7e39%). In any case, further studies are
needed to evaluate if the LAR or non-Basal-like subtypes beneﬁt
from antiandrogen. A phase II study with enzalutamide in 95 pa-
tients with metastatic TN but ARþ disease has completed recruit-
ment (NCT01889238).
Conclusions
Breast cancer is a clinically and biologically heterogeneous dis-
ease. However, the vast majority of the biological diversity coming
from the DNA, miRNAs and proteins is captured by the 4 main
intrinsic subtypesdeﬁnedbygeneexpression-only. At the same time,
and contrary to popular belief, intrinsic biology is not sufﬁciently
captured by standard clinical-pathological variables. In this review,
we have argued how intrinsic biology identiﬁed by gene expression
analyses provides, today and specially in the future, clinically rele-
vant information beyond the current pathology-based classiﬁcation
endorsed by the St. Gallen Consensus Panel. In the upcoming years,
we should expectmorewealth of data regarding the clinical utility of
intrinsic subtyping in a variety of clinical scenarios, and in combi-
nation with other biomarkers such as somatic mutations.
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